12/19
06:45 am
ocgn
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
Low
Report
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
12/19
06:38 am
ocgn
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Medium
Report
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
12/11
07:02 am
ocgn
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
Low
Report
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
11/27
07:19 am
ocgn
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference [Yahoo! Finance]
Medium
Report
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference [Yahoo! Finance]
11/27
07:09 am
ocgn
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
Medium
Report
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
11/20
07:39 am
ocgn
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease [Yahoo! Finance]
Low
Report
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease [Yahoo! Finance]
11/20
07:30 am
ocgn
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
Low
Report
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
11/19
01:08 pm
ocgn
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight [Yahoo! Finance]
Low
Report
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight [Yahoo! Finance]
11/19
07:15 am
ocgn
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
Medium
Report
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
11/19
07:02 am
ocgn
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Medium
Report
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
11/18
05:39 pm
ocgn
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Medium
Report
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
11/11
10:22 am
ocgn
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
11/11
08:10 am
ocgn
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Medium
Report
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
11/9
02:14 am
ocgn
Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
Medium
Report
Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
11/8
11:33 am
ocgn
Ocugen (OCGN) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Ocugen (OCGN) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
11/8
06:45 am
ocgn
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
High
Report
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
11/7
06:30 am
ocgn
Ocugen Secures $30 Million in Debt Funding
Medium
Report
Ocugen Secures $30 Million in Debt Funding
10/28
06:30 am
ocgn
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
Low
Report
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
10/23
08:18 am
ocgn
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
10/22
07:09 am
ocgn
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease [Yahoo! Finance]
Low
Report
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease [Yahoo! Finance]
10/22
07:02 am
ocgn
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
Low
Report
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
10/17
07:30 am
ocgn
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
Low
Report
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
10/15
08:12 am
ocgn
Ocugen, Inc. (NASDAQ: OCGN) is now covered by analysts at Maxim Group. They set a "buy" rating and a $4.00 price target on the stock.
Low
Report
Ocugen, Inc. (NASDAQ: OCGN) is now covered by analysts at Maxim Group. They set a "buy" rating and a $4.00 price target on the stock.
10/10
07:00 am
ocgn
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
Medium
Report
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
10/9
06:30 am
ocgn
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
Medium
Report
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial